Glaukos Co. (NYSE:GKOS) Stake Cut by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 3.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 105,956 shares of the medical instruments supplier's stock after selling 4,327 shares during the period. Segall Bryant & Hamill LLC owned about 0.19% of Glaukos worth $13,804,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new stake in shares of Glaukos during the 2nd quarter valued at $6,832,000. Natixis acquired a new position in shares of Glaukos during the 1st quarter worth approximately $614,000. Vanguard Group Inc. lifted its holdings in Glaukos by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock valued at $500,576,000 after purchasing an additional 72,159 shares in the last quarter. UniSuper Management Pty Ltd acquired a new stake in Glaukos in the 1st quarter worth about $913,000. Finally, WCM Investment Management LLC raised its stake in Glaukos by 45.7% in the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock valued at $12,721,000 after purchasing an additional 31,084 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Down 1.9 %

Shares of GKOS opened at $141.44 on Thursday. The firm has a market cap of $7.80 billion, a PE ratio of -46.83 and a beta of 1.02. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company's fifty day moving average is $131.75 and its two-hundred day moving average is $123.18. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $145.84.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) earnings per share. Analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current year.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GKOS. StockNews.com upgraded shares of Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Wells Fargo & Company boosted their price objective on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Piper Sandler set a $140.00 price objective on shares of Glaukos in a research report on Thursday, October 17th. Truist Financial raised their target price on Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. raised their price objective on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, Glaukos presently has an average rating of "Moderate Buy" and an average target price of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.